N-Hydroxy-3-phenyl-2-propenamides as Novel Inhibitors of Human Histone Deacetylase with in Vivo Antitumor Activity: Discovery of (2E)-N-Hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824)
IC50
DOI:
10.1021/jm030235w
Publication Date:
2003-10-02T04:28:23Z
AUTHORS (31)
ABSTRACT
A series of N-hydroxy-3-phenyl-2-propenamides were prepared as novel inhibitors human histone deacetylase (HDAC). These compounds potent enzyme inhibitors, having IC(50)s < 400 nM in a partially purified assay. However, potency cell growth inhibition assays ranged over 2 orders magnitude two carcinoma lines. Selected cellular IC(50) 750 tested for maximum tolerated dose (MTD) and efficacy the HCT116 colon tumor xenograft Four an MTD > or = 100 mg/kg selected dose-response studies model. One compound, 9 (NVP-LAQ824), had significant dose-related activity A549 lung models, high MTD, low gross toxicity. On basis, part, these properties, has entered clinical trials 2002.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (35)
CITATIONS (119)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....